Clinical Trials · NCT06699329
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 38
- Start date
- Jan 2024
- Locations
- 1 site, United States
- Primary endpoint
- Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Enlicitide Decanoate